Log in

Selecta Biosciences, Inc. (NASDAQ:SELB) Given Consensus Rating of "Hold" by Analysts

Last updated on Sunday, November 22, 2020 | 2020 MarketBeat

Shares of Selecta Biosciences, Inc. (NASDAQ:SELB) have received an average rating of "Hold" from the ten analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $4.50.

Several equities analysts recently commented on the stock. William Blair cut shares of Selecta Biosciences from an "outperform" rating to a "market perform" rating in a research note on Thursday, October 1st. Canaccord Genuity reaffirmed a "buy" rating on shares of Selecta Biosciences in a research note on Friday, August 7th. BidaskClub cut shares of Selecta Biosciences from a "buy" rating to a "hold" rating in a research note on Wednesday, November 4th. Zacks Investment Research lowered shares of Selecta Biosciences from a "hold" rating to a "sell" rating in a research report on Tuesday, August 18th. Finally, Mizuho lowered shares of Selecta Biosciences from a "buy" rating to a "neutral" rating and dropped their target price for the company from $7.00 to $2.50 in a research report on Thursday, October 1st.

In other Selecta Biosciences news, Director Timothy A. Springer acquired 3,185,394 shares of the stock in a transaction dated Thursday, October 8th. The stock was purchased at an average cost of $1.71 per share, for a total transaction of $5,447,023.74. Following the acquisition, the director now owns 7,293,625 shares in the company, valued at approximately $12,472,098.75. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Timothy A. Springer acquired 2,000,000 shares of the stock in a transaction dated Tuesday, October 6th. The stock was acquired at an average price of $1.68 per share, with a total value of $3,360,000.00. Following the completion of the acquisition, the director now owns 7,293,625 shares in the company, valued at approximately $12,253,290. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 9,061,490 shares of company stock valued at $18,332,395. 22.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. bought a new stake in shares of Selecta Biosciences in the 3rd quarter worth approximately $35,000. Verdence Capital Advisors LLC bought a new stake in shares of Selecta Biosciences in the 3rd quarter worth approximately $40,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Selecta Biosciences by 542.3% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 16,353 shares of the company's stock worth $41,000 after acquiring an additional 13,807 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Selecta Biosciences by 18.7% in the 1st quarter. Morgan Stanley now owns 21,636 shares of the company's stock worth $52,000 after acquiring an additional 3,412 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in Selecta Biosciences during the 2nd quarter valued at $57,000. Hedge funds and other institutional investors own 57.20% of the company's stock.

Shares of NASDAQ:SELB opened at $3.22 on Friday. The company has a 50 day moving average of $2.64 and a 200 day moving average of $2.79. The stock has a market cap of $347.86 million, a P/E ratio of -3.22 and a beta of 1.29. Selecta Biosciences has a 12 month low of $1.30 and a 12 month high of $4.83.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The firm had revenue of $4.65 million for the quarter, compared to analysts' expectations of $3.75 million. On average, equities analysts anticipate that Selecta Biosciences will post -0.55 earnings per share for the current year.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

See Also: Technical Analysis

Analyst Recommendations for Selecta Biosciences (NASDAQ:SELB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


15 Technology Stocks that Analysts Love

There are more than 1,100 technology companies traded on public markets in the United States. Given the sheer number of hardware makers, social networks, software companies, service providers and other tech stocks, it can be hard to identify which tech companies are going to outperform the market.

Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 15,000 distinct recommendations for technology companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same tech stock.

This slide show lists the 15 technology companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

View the "15 Technology Stocks that Analysts Love".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.